Premium
European Study on Orthopaedic Status of haemophilia patients with inhibitors
Author(s) -
MORFINI M.,
HAYA S.,
TAGARIELLO G.,
POLLMANN H.,
QUINTANA M.,
SIEGMUND B.,
STIELTJES N.,
DOLAN G.,
TUSELL J.
Publication year - 2007
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2007.01518.x
Subject(s) - medicine , haemophilia , haemophilia a , observational study , quality of life (healthcare) , group b , orthopedic surgery , arthropathy , group a , demographics , pediatrics , physical therapy , surgery , osteoarthritis , alternative medicine , pathology , nursing , demography , sociology
Summary. Development of inhibitors against factor VIII (FVIII) or factor IX (FIX) in haemophilia patients is one of the most serious complications of repeated exposure to replacement therapy and has major clinical and economic consequences. To evaluate the relationship between inhibitor status of haemophilia patients and their quality of life (QoL) and degree of arthropathy and to compare the orthopaedic status of patients with/without inhibitors. An observational, cross‐sectional, case control study enrolling: group A ( n = 38), males aged 14–35 years, with severe congenital haemophilia A or B who had inhibitors against FVIII/FIX >5 years; group B ( n = 41), as group A, but aged 36–65 years and group C ( n = 49), as group A, but without inhibitors. Socio‐demographics: medical history, clinical characteristics and QoL were assessed. In groups A and B, 16% and 27% were hospitalized for orthopaedic procedures vs. 4% in group C. Patient mobility was also severely reduced in groups A and B, with 24% and 22% using wheelchairs vs. 4% in group C, and 50% and 51% needing a walking aid vs. 29% in group C. Significantly more joint pain was reported by patients in group A vs. those in group C; clinical/radiological orthopaedic scores were also worse in group A vs. group C. Significantly more joint abnormality was reported by patients in group A vs. group C. The burden of orthopaedic complications and the impact on QoL are more severe in haemophilia patients who have developed inhibitors than in those without inhibitors.